After completing his studies in law, Rolf Hänggi worked in financial and investment analysis, fund management, mortgages and financing. At the Zurich Group, he held the position of Head of Finance and Global Investments worldwide, and acted as Deputy CEO of the Corporate Executive Board for several years. He served as Chairman or Board Member of Zurich Insurance Company, Rüd Blass & Cie AG Bankers and Speedel Holding. He was Vice-Chairman of the Board of Roche Holding AG and Nestlé AG. He is member of the Advisory Board for the Master course of Advanced Studies in Applied History, and past member of the Board of Trustees of the Foundation Luftbild Schweiz and of the Werner Abegg Foundation. Rolf Hänggi is graduate of the School of Law at the University of Basel and received an ISMP from the International Senior Managers Program at Harvard Business School.
Alcide Barberis is a biotech entrepreneur with over 20 years management experience in the biotechnology industry and scientific experience in the private and public research sectors. He was a co-founder and a Board Member of ESBATech AG and Oncalis AG, and is currently member of the Board of Directors of EffRx Pharmaceutical AG. In 2016 he founded LCID Consulting LLC and has directed CP Start-Up, a service promoted by the Foundation for the Lugano Faculties of USI aimed at supporting start-up companies in Southern Switzerland. Dr. Barberis holds a Ph.D. in Molecular Biology and Biochemistry from the University of Zürich.
Adriano Aguzzi directs the Institute of Neuropathology at the University of Zurich. His research focuses on prions - exploring how they damage brain cells, why they accumulate in lymphoid organs, and how they reach the brain after entering the body from peripheral sites. Prof. Aguzzi has provided the first evidence that prions can be halted in vivo with therapeutic antibodies (Heppner et al., Science 2001) and that epitope specificity is crucial to the action of such antibodies (Sonati et al., Nature 2013). His lab has discovered the prion protein receptor (Küffer et al., Nature 2016). Prof. Aguzzi is the Director of the MD-PhD program at the University of Zurich and Past President of the Swiss Society of Neuropathology. He is the Founding Director of the Swiss National Reference Center for Prion Diseases. Prof. Aguzzi has patented diagnostic and therapeutic methods in the prion field. He has advised the British, Italian, and Swiss government on prion diseases. He serves on the editorial board of the journal Science and is Editor-in-Chief of the Swiss Medical Weekly. Among other honors, Prof. Aguzzi has won the Ernst-Jung, Marcel-Benoist, Baillet-Latour, and Robert-Koch Prizes as well as the Gold Medal of the European Molecular Biology Organization (EMBO). He was awarded three Doctorates honoris causa from the Universities of Bologna, Teramo, and Liege.
Regula Dannecker studied law at the University of Zürich. She holds a Master in Law from the University of Cape Town and a Certificate of Advanced Studies (CAS) in International Contract Law and Arbitration from the University of Zürich. Following her admission to the bar association of the canton of Zürich she worked with Ernst & Young AG in Zürich and for almost eight years with law firms in Cape Town and Johannesburg as a legal advisor to companies and individuals with a focus on international matters. Regula Dannecker is a member of the board of SwissCham Southern Africa. Since 2009 she has been working as an attorney with the law firm weber schaub & partner ag, specializing in corporate and contract law and international private law. Regula Dannecker has been serving on the Board of Directors of Mabylon since its inception in 2011.